| 1 |
NCT02914067 |
Recruiting |
Cognitive Biomarkers in Pediatric Brain Tumor Patients |
|
- Other: Neurocognitive testing
- Device: rsfcMRI
|
Interventional |
Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Identify reliable peri-diagnostic estimators of cognition as measured by neurocognitive testing
- Identify reliable peri-diagnostic estimators of cognition as measured by advanced resting-state functional connectivity MRI (rsfcMRI) data
- Predictors of cognitive recovery in children as determined by multiplexed analyses of a combination of potential biomarkers across multiple modalities (rsfcMRI, structural MRI, NIH Toolbox, patient demographics, treatment information)
- (and 2 more...)
|
60 |
All |
4 Years to 18 Years (Child, Adult) |
NCT02914067 |
201609023 |
|
October 26, 2016 |
November 30, 2019 |
January 30, 2022 |
September 26, 2016 |
March 7, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
| 2 |
NCT03451123 |
Not yet recruiting |
FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors |
|
|
Interventional |
Early Phase 1 |
- University of Alabama at Birmingham
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Percentage of patients whose surgical plan change with FET-PET/MRI compared to MRI alone.
- Percentage of patients who have residual tumor after surgery detected with FET-PET/MRI
|
12 |
All |
6 Years to 18 Years (Child, Adult) |
NCT03451123 |
R17-077 |
|
April 2018 |
February 2021 |
February 2021 |
March 1, 2018 |
March 2, 2018 |
|
|
| 3 |
NCT03234309 |
Recruiting |
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors |
|
- Drug: Ferumoxytol
- Procedure: Magnetic Resonance Imaging
|
Interventional |
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Cerebral blood volume in small (< 1cm) enhancing lesions
- Confidence in identifying the lesion corresponding areas on cerebral blood volume maps
- Delineation of tumor from larger blood vessels
- (and 7 more...)
|
100 |
All |
5 Years to 18 Years (Child, Adult) |
NCT03234309 |
STUDY00016165
NCI-2017-00713
P30CA069533 |
|
October 20, 2017 |
April 14, 2021 |
April 14, 2022 |
July 31, 2017 |
November 6, 2017 |
|
- OHSU Knight Cancer Institute
Portland, Oregon, United States
|
| 4 |
NCT03179449 |
Recruiting |
In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI |
|
- Diagnostic Test: Diagnostic (ferumoxytol-enhanced MRI)
- Procedure: Surgery
- Drug: Ferumoxytol
- Other: Tissue Analysis
|
Interventional |
Early Phase 1 |
- Michael Iv
- National Cancer Institute (NCI)
- Stanford University
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Iron concentration measurements
- Macrophages on histopathology
|
10 |
All |
2 Years and older (Child, Adult, Senior) |
NCT03179449 |
PEDSBRNCNS0008
NCI-2017-00959
P30CA124435
IRB-39245 |
|
July 1, 2017 |
July 1, 2019 |
July 1, 2019 |
June 7, 2017 |
July 18, 2017 |
|
- Stanford University, School of Medicine
Palo Alto, California, United States
|
| 5 |
NCT03208387 |
Recruiting |
Understanding the Late Effects of Surviving a Pediatric Brain Tumor |
- Brain Tumor
- Pediatric Brain Tumor
- Pediatric Cancer
|
- Diagnostic Test: Diffusion tensor imaging (DTI)
- Diagnostic Test: Resting state functional connectivity MRI (rs-fcMRI)
- Behavioral: Wechsler Intelligence Scale for Children - 5th edition (WISC-V)
- (and 5 more...)
|
Observational |
|
- Memorial Sloan Kettering Cancer Center
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Feasibilty which is the number of eligible survivors consented per month
|
48 |
All |
6 Years to 16 Years (Child) |
NCT03208387 |
17-338 |
|
June 28, 2017 |
June 2019 |
June 2019 |
July 5, 2017 |
February 15, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States - University of Texas Southwestern Medical Center
Dallas, Texas, United States - Seattle Children's Hospital
Seattle, Washington, United States
|
| 6 |
NCT00978562 |
Active, not recruiting
Has Results |
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors |
- Childhood Brain Neoplasm
- Recurrent Childhood Brain Neoplasm
|
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
- Drug: Ferumoxytol Non-Stoichiometric Magnetite
- Drug: Gadolinium
|
Interventional |
Not Applicable |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Vascular Properties of Pediatric Brain Tumors Using Dynamic Susceptibility-weighted Contrast Enhanced MRI (DSC-MRI) After Administration of Ferumoxytol
- Vascular Properties of Pediatric Brain Tumors Using Dynamic Contrast-enhanced MRI (DCE-MRI) After Administration of a Gadolinium-based Contrast Agent
- Histology (Only in Patients for Whom a Biopsy or Surgery is Scheduled Outside of This Protocol)
- (and 4 more...)
|
7 |
All |
5 Years to 18 Years (Child, Adult) |
NCT00978562 |
IRB00005405
NCI-2015-00227
1562
2864
SOL-09064-LX
813
5405
P30CA069533 |
|
August 2009 |
December 2015 |
December 2018 |
September 17, 2009 |
February 1, 2018 |
May 23, 2017 |
- OHSU Knight Cancer Institute
Portland, Oregon, United States
|
| 7 |
NCT03334162 |
Not yet recruiting |
Playful Sensorimotor Training in Pediatric Brain Tumor Patients |
- Pediatric Cancer
- Pediatric Brain Tumor
- Chemotherapy-induced Peripheral Neuropathy
- Sensorimotor Polyneuropathy
|
- Behavioral: Sensorimotor training
|
Interventional |
Not Applicable |
- University of Basel
- University Children's Hospital Basel
- Kantonsspital Aarau
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Ped-mTNS score (assesses the change in the severity of CIPN symptoms)
- Nerve conduction studies
- short clinical test battery for CIPN
- (and 8 more...)
|
20 |
All |
6 Years to 18 Years (Child, Adult) |
NCT03334162 |
RESET-study |
RESET |
November 2017 |
November 2020 |
November 2020 |
November 7, 2017 |
November 7, 2017 |
|
|
| 8 |
NCT03330197 |
Recruiting |
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG |
- Pediatric Brain Tumor
- Diffuse Intrinsic Pontine Glioma
|
- Biological: Ad-RTS-hIL-12
- Drug: oral veledimex
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The safety and tolerability of intratumoral Ad-RTS-hIL-12 and veledimex as measured by dose limiting toxicities and compliance.
- To measure the veledimex in blood and brain tumor by using the LC-MS method
- Evaluate preliminary efficacy of Ad-RTS-hIL-12 and veledimex by assessing survival and tumor response rates
- (and 2 more...)
|
24 |
All |
up to 21 Years (Child, Adult) |
NCT03330197 |
ATI001-103 |
|
September 26, 2017 |
March 2021 |
March 2021 |
November 6, 2017 |
March 30, 2018 |
|
- Lurie Children's Hospital of Chicago
Chicago, Illinois, United States - Dana- Farber Cancer Institute
Boston, Massachusetts, United States
|
| 9 |
NCT03068832 |
Not yet recruiting |
Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors |
|
- Biological: Personalized peptide vaccine
- Drug: Poly ICLC
- Procedure: Peripheral blood draw
|
Interventional |
Phase 1 |
- Washington University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of adjuvant personalized neoantigen peptide vaccine administration with poly-ICLC as measured by grade 3 and 4 adverse events
- Feasibility of adjuvant personalized neoantigen peptide vaccine administration with poly-ICLC as measured by the number of participants who have a neoantigen specific long peptide vaccine identified and generated
- Characterize tumor-infiltrating lymphocytes (TIL)
- Frequency of expressed neoantigens using patient-specific HLA class I prediction algorithms
|
10 |
All |
up to 21 Years (Child, Adult) |
NCT03068832 |
17-x032 |
|
May 31, 2018 |
November 30, 2019 |
October 31, 2022 |
March 3, 2017 |
January 25, 2018 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
| 10 |
NCT02947373 |
Recruiting |
Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors |
|
- Drug: Hyperpolarized Pyruvate
|
Interventional |
Phase 1 |
- University of California, San Francisco
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of Participants With Adverse Events as Assessed by CTCAE v4.0. Analyses will be performed for all patients having received at least one dose of study drug.
- Secondary analyses will include assessment of imaging quality, which will be descriptive in nature.
|
9 |
All |
3 Years to 18 Years (Child, Adult) |
NCT02947373 |
PNOC 011
16088 |
|
January 25, 2017 |
November 2018 |
February 2019 |
October 27, 2016 |
February 7, 2018 |
|
- UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
|
| 11 |
NCT02573441 |
Recruiting |
KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer |
|
- Behavioral: Jump Math
- Behavioral: Cogmed
- Behavioral: Liaison Services
|
Interventional |
Not Applicable |
- The Hospital for Sick Children
- Pediatric Oncology Group of Ontario
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Woodcock Johnson Academic-Third Edition
- Wechsler Intelligence Scale for Children - Fourth Edition Integrated
- Wide Range Assessment of Memory and Learning - Second Edition
- (and 9 more...)
|
45 |
All |
6 Years to 17 Years (Child) |
NCT02573441 |
1000043747 |
|
October 2015 |
October 2017 |
October 2018 |
October 9, 2015 |
October 28, 2016 |
|
- Hospital for Sick Children
Toronto, Ontario, Canada
|
| 12 |
NCT02417324 |
Recruiting |
International HIT-MED Registry (I-HIT-MED) |
|
|
Observational |
|
- Universitätsklinikum Hamburg-Eppendorf
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Event free survival
- Pattern of relapse
- Overall survival
|
500 |
All |
Child, Adult, Senior |
NCT02417324 |
I-HIT-MED Registry |
|
January 2015 |
December 2019 |
December 2024 |
April 15, 2015 |
October 18, 2017 |
|
- University Hospital Aachen
Aachen, Germany - Klinikum Augsburg
Augsburg, Germany - Helios Klinikum Berlin-Buch
Berlin, Germany - (and 54 more...)
|
| 13 |
NCT00003476 |
Terminated
Has Results |
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors |
|
- Drug: Antineoplaston therapy (Atengenal + Astugenal)
|
Interventional |
Phase 2 |
- Burzynski Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Objective Response
- Percentage of Participants Who Survived
|
8 |
All |
6 Months to 18 Years (Child, Adult) |
NCT00003476 |
CDR0000066513
BC-BT-22 |
|
March 1996 |
January 2012 |
January 2012 |
January 27, 2003 |
August 24, 2017 |
April 10, 2017 |
- Burzynski Clinic
Houston, Texas, United States
|
| 14 |
NCT00003458 |
Completed
Has Results |
Antineoplaston Therapy in Treating Children With Brain Tumors |
|
- Drug: Antineoplaston therapy (Atengenal + Astugenal)
|
Interventional |
Phase 2 |
- Burzynski Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Objective Response
- Percentage of Participants Who Survived
|
34 |
All |
6 Months to 18 Years (Child, Adult) |
NCT00003458 |
CDR0000066490
BC-BT-10 |
|
September 1996 |
September 2014 |
September 2014 |
January 27, 2003 |
February 2, 2018 |
January 19, 2017 |
- Burzynski Clinic
Houston, Texas, United States
|
| 15 |
NCT02015728 |
Active, not recruiting |
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors |
- Recurrent Childhood Brain Tumor
|
- Device: Tumor biology testing
- Drug: Temozolomide
- Drug: Etoposide
- (and 4 more...)
|
Interventional |
Not Applicable |
- Seattle Children's Hospital
- Cures Within Reach
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility
- Efficacy
- Survival
- Toxicity
|
20 |
All |
1 Month to 30 Years (Child, Adult) |
NCT02015728 |
SC-9006 |
SEED |
December 2013 |
November 2016 |
December 2017 |
December 19, 2013 |
December 15, 2016 |
|
- Seattle Children's
Seattle, Washington, United States
|
| 16 |
NCT03216148 |
Recruiting |
18F-FET PET in Childhood Brain Tumours |
|
|
Interventional |
Phase 2 |
- Charite University, Berlin, Germany
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Differentiating biologically active Tumor tissue from therapy related changes by using MRI (Magnetic Resonance Imaging) and FET PET
- Sensitivity of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET
- Assessment of the predictive value of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET
- (and 2 more...)
|
160 |
All |
1 Year to 17 Years (Child) |
NCT03216148 |
FET PET 2010
2008-005786-60 |
|
July 2015 |
July 2018 |
July 2019 |
July 13, 2017 |
July 21, 2017 |
|
- Klinikum Augsburg, Onkologie
Augsburg, Germany - Charité Universitätsmedizin Berlin, CVK, Onkologie
Berlin, Germany - Evangelisches Krankenhaus Bielefeld gGmbH, Onkologie
Bielefeld, Germany - (and 19 more...)
|
| 17 |
NCT03361033 |
Recruiting |
Components of Social Functioning in Survivors of Pediatric Brain Tumors |
- Brain Tumor, Pediatric
- Medulloblastoma, Pediatric
|
|
Observational |
|
- St. Jude Children's Research Hospital
- American Cancer Society, Inc.
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Significant predictors of social-cognitive and neurocognitive abilities on social functioning
|
68 |
All |
8 Years to 12 Years (Child) |
NCT03361033 |
SOCFUN |
|
January 30, 2018 |
February 2021 |
February 2021 |
December 4, 2017 |
February 1, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 18 |
NCT01650922 |
Completed |
Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples |
|
- Procedure: phlebotomy
- Procedure: biopsy
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
4 |
All |
up to 24 Years (Child, Adult) |
NCT01650922 |
PEDSBRN0004
96447 |
|
September 2005 |
September 2008 |
September 2008 |
July 26, 2012 |
July 26, 2012 |
|
- Stanford University School of Medicine
Stanford, California, United States
|
| 19 |
NCT02644291 |
Recruiting |
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors |
- Medulloblastoma
- Astrocytoma, Grade III
- Glioblastoma
- (and 5 more...)
|
|
Interventional |
Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse events attributed to mebendazole for patients enrolled in this study
- Overall survival for patients enrolled in this study
|
21 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02644291 |
J15211
IRB00072999 |
|
May 2016 |
June 2019 |
June 2020 |
December 31, 2015 |
June 1, 2017 |
|
- Johns Hopkins All Children's Hospital
Saint Petersburg, Florida, United States - Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
|
| 20 |
NCT02129712 |
Recruiting |
Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors |
|
- Behavioral: Cognitive training
|
Interventional |
Not Applicable |
- Vanderbilt University
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- NIH Toolbox-Cognition Battery
|
40 |
All |
7 Years to 16 Years (Child) |
NCT02129712 |
121214
1R21CA175840-01 |
CRPBT |
February 1, 2014 |
December 31, 2017 |
December 31, 2017 |
May 2, 2014 |
April 12, 2017 |
|
- Vanderbilt University
Nashville, Tennessee, United States
|
| 21 |
NCT01556178 |
Completed |
Blood and Cerebrospinal Fluid for Pediatric Brain Tumor Research |
|
|
Observational |
|
- Ann & Robert H Lurie Children's Hospital of Chicago
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- levels of miRNAs in the blood and CSF
- Survivin and biologic markers levels in the CSF and blood
|
5 |
All |
1 Year to 21 Years (Child, Adult) |
NCT01556178 |
2011-14612 |
|
July 2011 |
April 2012 |
April 2012 |
March 16, 2012 |
February 5, 2016 |
|
- Children's Memorial Hospital
Chicago, Illinois, United States
|
| 22 |
NCT01902771 |
Terminated |
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors |
- Glioma
- Brain Cancer
- Brain Tumor
- (and 2 more...)
|
- Biological: Dendritic Cell Vaccine
- Biological: Tumor Lysate
- Other: Imiquimod
- Procedure: Leukapheresis
|
Interventional |
Phase 1 |
- Edward Ziga
- University of Miami
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of Toxicity in Study Participants Receiving Protocol Therapy
- Rate of Feasibility of Protocol Therapy in Study Participants
- Rate of Prolonged Survival or Prolonged Progression-Free Survival in Study Participants
- (and 4 more...)
|
1 |
All |
1 Year to 29 Years (Child, Adult) |
NCT01902771 |
20130136 |
|
September 3, 2013 |
October 24, 2016 |
January 26, 2017 |
July 18, 2013 |
March 10, 2017 |
|
- University of Miami
Miami, Florida, United States
|
| 23 |
NCT03399864 |
Recruiting |
Effectiveness of Musical Training in Hong Kong Chinese Childhood Brain Tumor Survivors |
|
- Behavioral: musical training
- Other: usual care
|
Interventional |
Not Applicable |
- The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Change in depressive symptoms from baseline at 12-month follow-up between intervention and control group.
- Depressive symptoms at baseline between intervention and control group
- Change in depressive symptoms from baseline at 6-month follow-up between intervention and control group
- (and 6 more...)
|
68 |
All |
7 Years to 16 Years (Child) |
NCT03399864 |
UW16-023_2 |
|
February 20, 2017 |
August 31, 2018 |
August 31, 2018 |
January 16, 2018 |
February 7, 2018 |
|
- The University of Hong Kong
Hong Kong, China
|
| 24 |
NCT00003096 |
Completed |
Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors |
- Brain Tumors
- Central Nervous System Tumors
|
- Genetic: DNA ploidy analysis
- Genetic: comparative genomic hybridization
- Genetic: cytogenetic analysis
- Genetic: fluorescence in situ hybridization
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Frequency of specific chromosomal gains, losses and rearrangements in a series of infratentorial and supratentorial PNETS
|
88 |
All |
up to 20 Years (Child, Adult) |
NCT00003096 |
B971
COG-B971
CCG-B971
CDR0000065814 |
|
December 1996 |
March 2006 |
March 2007 |
January 27, 2003 |
August 6, 2014 |
|
- Phoenix Children's Hospital
Phoenix, Arizona, United States - Southern California Permanente Medical Group
Downey, California, United States - Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California, United States - (and 58 more...)
|
| 25 |
NCT00693914 |
Completed |
Working Memory Performance Among Childhood Brain Tumor Survivors |
|
- Behavioral: Series of tests/questionnaires
|
Observational |
|
- St. Jude Children's Research Hospital
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Performance on experimental working memory measures (computerized self-ordered pointing tasks)
- Abbreviated IQ (WASI), episodic memory measures (computerized word and face recognition tasks) and parent questionnaires of executive (BRIEF) and adaptive (ABAS-II) functioning.
|
130 |
All |
8 Years to 18 Years (Child, Adult) |
NCT00693914 |
EXFXN1
R21CA131616 |
|
April 2007 |
December 2009 |
December 2009 |
June 9, 2008 |
April 25, 2017 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 26 |
NCT00907244 |
Completed |
Arterial Spin Labeling Perfusion Magnetic Resonance (MR) Imaging in Pediatric Brain Tumors |
|
|
Observational |
|
- Children's Hospital of Philadelphia
- Thrasher Research Fund
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
13 |
All |
up to 18 Years (Child, Adult) |
NCT00907244 |
CHP 901 ASL
2008-4-5917 |
|
April 2008 |
July 2012 |
July 2012 |
May 22, 2009 |
October 29, 2012 |
|
- The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 27 |
NCT01288235 |
Active, not recruiting |
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation |
- Brain Tumor
- Low Grade Glioma
- Astrocytoma
- (and 2 more...)
|
- Radiation: Proton radiotherapy
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
- Dana-Farber Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Endocrine dysfunction
- Neurocognitive sequelae
- Disease control
- (and 2 more...)
|
100 |
All |
1 Year to 25 Years (Child, Adult) |
NCT01288235 |
10-206 |
|
January 2011 |
January 2020 |
January 2020 |
February 2, 2011 |
October 17, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 28 |
NCT01067196 |
Completed |
Outcomes Study of Late Effects After Proton RT for Pediatric Tumors of the Brain, Head, and Neck |
- Central Nervous System Tumors
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Measure late effects of proton therapy on pediatric patients with CNS tumors
- Survival endpoints of local control, progression-free survival, and overall and cause-specific survival.
|
442 |
All |
up to 20 Years (Child, Adult) |
NCT01067196 |
IRB201701741
UFPTI 0903-CN01 |
CN01 |
February 2010 |
December 2015 |
December 2015 |
February 11, 2010 |
July 21, 2017 |
|
- University of Florida Proton Therapy Institute
Jacksonville, Florida, United States
|
| 29 |
NCT00165542 |
Completed |
A-protein Levels in Adult and Pediatric Brain Tumor Patients |
- Malignant Childhood Central Nervous System Neoplasm
|
|
Observational |
|
- Dana-Farber Cancer Institute
- Brigham and Women's Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- association between serum A-Protein level class and clinical status
|
54 |
All |
up to 77 Years (Child, Adult, Senior) |
NCT00165542 |
98-137 |
|
June 1998 |
February 2004 |
August 2009 |
September 14, 2005 |
November 23, 2016 |
|
- Dana Farber Cancer Institite
Boston, Massachusetts, United States
|
| 30 |
NCT02372409 |
Recruiting |
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors |
- Glioma
- Pilocytic Astrocytoma
- Anaplastic Astrocytoma
- (and 6 more...)
|
- Device: MRI-guided laser ablation
- Drug: Doxorubicin
- Drug: Etoposide
- (and 2 more...)
|
Interventional |
Phase 1 |
- Washington University School of Medicine
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Arm A only: Progression-free survival (PFS)
- Arm A only: Overall survival (OS)
- Arm B only: Progression-free survival (PFS)
- (and 4 more...)
|
12 |
All |
3 Years to 21 Years (Child, Adult) |
NCT02372409 |
201502062 |
|
August 14, 2015 |
October 30, 2019 |
October 30, 2019 |
February 26, 2015 |
October 2, 2017 |
|
- Washington University School of Medicine
Saint Louis, Missouri, United States
|
| 31 |
NCT00634231 |
Active, not recruiting |
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors |
- Malignant Glioma
- Recurrent Ependymoma
|
- Biological: AdV-tk
- Drug: valacyclovir
- Radiation: Radiation
|
Interventional |
Phase 1 |
- Advantagene, Inc.
- Boston Children’s Hospital
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety based on standard laboratory and clinical adverse event monitoring
- Overall survival
- Progression-free survival
- (and 2 more...)
|
12 |
All |
3 Years to 21 Years (Child, Adult) |
NCT00634231 |
07-098 |
|
April 2010 |
December 2015 |
December 2020 |
March 12, 2008 |
January 10, 2018 |
|
- Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)
Chicago, Illinois, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 32 |
NCT00666614 |
Completed |
A Pilot Study to Examine Sleep and Fatigue in Pediatric Brain Tumor Patients Hospitalized for High Dose Chemotherapy |
|
- Other: Sleep Environment Intervention
- Other: Normal Hospital Environment
|
Interventional |
Not Applicable |
- St. Jude Children's Research Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- To assess sleep quality, fatigue and daytime activity during the 4 to 6-day hospitalization as being more positive for patients randomized to the sleep environment intervention months as compared to those randomized to the standard care months
|
43 |
All |
4 Years to 21 Years (Child, Adult) |
NCT00666614 |
BTSLEP |
|
April 2008 |
October 2011 |
October 2011 |
April 25, 2008 |
January 5, 2012 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 33 |
NCT00006342 |
Completed |
Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor |
- Brain and Central Nervous System Tumors
- Lymphoma
|
- Genetic: chromosomal translocation analysis
- Genetic: gene rearrangement analysis
- Genetic: mutation analysis
|
Observational |
|
- Duke University
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
19 |
All |
Child, Adult, Senior |
NCT00006342 |
CDR0000067681
DUMC-0113-99-1R2
DUMC-IRB-086-97-1
NCI-G00-1840 |
|
January 1997 |
September 2000 |
January 2001 |
May 4, 2004 |
October 15, 2015 |
|
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States
|
| 34 |
NCT01707836 |
Completed |
Neurofibromatosis Type 1 Brain Tumor Genetic Risk |
- Neurofibromatosis Type 1
- Pediatric Brain Tumor
|
|
Observational |
|
- Washington University School of Medicine
|
Other |
- Observational Model: Family-Based
- Time Perspective: Cross-Sectional
|
|
176 |
All |
up to 18 Years (Child, Adult) |
NCT01707836 |
201208141 |
|
October 2012 |
May 8, 2017 |
May 8, 2017 |
October 16, 2012 |
May 9, 2017 |
|
- Washington University
Saint Louis, Missouri, United States
|
| 35 |
NCT01503086 |
Recruiting |
Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy |
- Childhood Brain Tumor
- Cognitive/Functional Effects
- Neurotoxicity
- (and 2 more...)
|
- Other: computer-assisted cognitive training
- Other: questionnaire administration
- Procedure: cognitive assessment
- (and 2 more...)
|
Interventional |
Not Applicable |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intervention compliance defined as at least 80% of sessions completed (i.e., completing at least 20 sessions within 9 weeks of starting training)
- Parent-rated executive function and WM using the Metacognition subscales from the Behavior Rating Inventory of Executive Function (BRIEF)
- Executive function using the Groton Maze Learning and Set Shifting tasks of the CogState battery
- (and 5 more...)
|
71 |
All |
6 Years to 16 Years (Child) |
NCT01503086 |
ACCL10P1
NCI-2012-00112
CDR0000721387
COG-ACCL10P1
U10CA095861 |
|
November 2013 |
April 2018 |
April 2018 |
January 2, 2012 |
July 12, 2017 |
|
- Children's Oncology Group
Arcadia, California, United States - Children's National Medical Center
Washington, D.C., District of Columbia, United States - Washington University School of Medicine
Saint Louis, Missouri, United States - (and 6 more...)
|
| 36 |
NCT00961922 |
Unknown † |
Pediatric Research on Improving Speed, Memory and Attention |
|
- Other: Neurofeedback
- Other: Placebo feedback
|
Interventional |
Not Applicable |
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Dutch Cancer Society
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Neurocognitive functioning
- psychosocial functioning
|
105 |
All |
8 Years to 18 Years (Child, Adult) |
NCT00961922 |
UVA 2008-4013
MEC 09/137 |
PRISMA |
January 2010 |
October 2013 |
July 2014 |
August 19, 2009 |
October 4, 2012 |
|
- Academic Medical Centre - UvA
Amsterdam, Noord Holland, Netherlands
|
| 37 |
NCT03478462 |
Not yet recruiting
New |
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma |
- Pediatric Solid Tumor
- Pediatric Lymphoma
- Pediatric Brain Tumor
|
|
Interventional |
Phase 1 |
- Cellectar Biosciences, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with dose limiting toxicities (DLT)
- Determination of therapeutic activity of CLR 131 in children and adolescents
|
30 |
All |
2 Years to 21 Years (Child, Adult) |
NCT03478462 |
DCL-17-001 |
|
July 2018 |
September 2020 |
December 2020 |
March 27, 2018 |
March 27, 2018 |
|
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
| 38 |
NCT02160795 |
Completed |
Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer. |
- Pediatric Leukemia
- Pediatric Brain Neoplasms
- Other Pediatric Cancers
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
39456 |
All |
17 Years to 20 Years (Child, Adult) |
NCT02160795 |
999914093
14-C-N093 |
|
June 7, 2014 |
February 23, 2018 |
February 23, 2018 |
June 11, 2014 |
March 2, 2018 |
|
- National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 39 |
NCT01682746 |
Recruiting |
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors |
|
- Drug: Photofrin (porfimer sodium) & photodynamic therapy.
|
Interventional |
Phase 1 |
- Harry T Whelan, MD
- Pinnacle Biologics Inc.
- Medical College of Wisconsin
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerable dose (MTD) of Photofrin® in pediatric subjects
- Brain tumor response
|
24 |
All |
6 Months to 18 Years (Child, Adult) |
NCT01682746 |
163588-1 |
|
March 2013 |
April 2019 |
April 2024 |
September 11, 2012 |
February 20, 2018 |
|
- Children's Hospital of Wisconsin
Wauwatosa, Wisconsin, United States
|
| 40 |
NCT01180881 |
Active, not recruiting |
Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment |
- Brain Tumor
- Central Nervous System Neoplasms
|
|
Observational |
|
- Massachusetts General Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Behavior Rating Inventory of Executive Functioning
- Behavior Assessment System for Children
- Scales of Independent Behavior-Revised
|
150 |
All |
2 Years to 25 Years (Child, Adult) |
NCT01180881 |
2009A058394 |
|
October 2009 |
July 2018 |
July 2018 |
August 12, 2010 |
August 30, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 41 |
NCT00002647 |
Unknown † |
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
|
- Drug: verteporfin
- Procedure: conventional surgery
|
Interventional |
Phase 1 |
- Medical College of Wisconsin
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
|
24 |
All |
3 Years to 70 Years (Child, Adult, Senior) |
NCT00002647 |
CDR0000064165
MCW-7594
MCW-CHW-511
MCW-CHW-9411
NCI-V95-0652 |
|
May 1994 |
|
|
January 27, 2003 |
September 20, 2013 |
|
- Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States - Midwest Children's Cancer Center at Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
| 42 |
NCT01342237 |
Unknown † |
Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors |
|
- Drug: HDCT 1(TTC), HDCT2(MEC)
|
Interventional |
Phase 2 |
- Seoul National University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate event free survival rate
- To evaluate treatment related mortality
- To evaluate the incidence and severity of toxicity
- To evaluate overall survival rate and relapse rate
|
33 |
All |
Child, Adult, Senior |
NCT01342237 |
SNUCH-SCT-1102 |
|
March 2011 |
February 2014 |
February 2014 |
April 27, 2011 |
November 19, 2013 |
|
- Seoul National University Hospital
Seoul, Daehangno, Jongno-gu, Korea, Republic of
|
| 43 |
NCT00187226 |
Completed
Has Results |
A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects |
- Central Nervous System Tumors
- Brain Tumors
|
- Procedure: Radiation Therapy
|
Interventional |
Phase 2 |
- St. Jude Children's Research Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
202 |
All |
8 Months to 25 Years (Child, Adult) |
NCT00187226 |
RT1 |
|
June 1997 |
March 2005 |
March 2005 |
September 16, 2005 |
August 20, 2012 |
August 20, 2012 |
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 44 |
NCT00067821 |
Recruiting |
Comparison of PET and Proton MRS Imaging to Evaluate Pediatric Brain Tumor Activity |
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Compare results from Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI) and [18F]-FDG Positron Emission Tomography (PET) in brain tumors
- Correlate results of compare results from Proton Magnetic Resonance Spectroscopic Imaging (1H-MRSI) and [18F]- FDG Positron Emission Tomography (PET) with MRI
- To evaluate changes over time in brain tumors
|
150 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00067821 |
030278
03-C-0278 |
|
August 27, 2003 |
|
|
August 28, 2003 |
March 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 45 |
NCT00919750 |
Active, not recruiting |
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors |
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Choroid Plexus Tumor
- (and 17 more...)
|
- Other: cytology specimen collection procedure
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Collection of brain tumor tissue and an accompanying blood sample from pediatric patients with brain tumors treated at Children's Oncology Group institutions
- Creation of a repository for long-term storage of these specimens
- Making these specimens available to qualified researchers to understand the biology of pediatric brain tumors
|
5000 |
All |
up to 18 Years (Child, Adult) |
NCT00919750 |
ACNS02B3
NCI-2009-00334
COG-ACNS02B3
CDR0000352347
U10CA098543 |
|
March 2005 |
January 2100 |
January 2100 |
June 12, 2009 |
December 13, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 165 more...)
|
| 46 |
NCT00452868 |
Completed
Has Results |
Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain |
- Brain and Central Nervous System Tumors
- Cognitive/Functional Effects
- Long-term Effects Secondary to Cancer Therapy in Children
- (and 3 more...)
|
|
Interventional |
Early Phase 1 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Neurocognitive Function as Measured by the Neurocognitive Battery at 24 Weeks
|
14 |
All |
8 Years to 17 Years (Child) |
NCT00452868 |
CDR0000537049
P30CA012197
CCCWFU-91305
CCCWFU-IRB-00000258 |
|
June 2006 |
February 2010 |
February 2010 |
March 28, 2007 |
August 30, 2017 |
February 28, 2013 |
- Tufts-NEMC Cancer Center
Boston, Massachusetts, United States - Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
|
| 47 |
NCT00019422 |
Completed |
Lobradimil and Carboplatin in Treating Children With Brain Tumors |
- Brain and Central Nervous System Tumors
|
- Drug: carboplatin
- Drug: lobradimil
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- Children's Oncology Group
|
NIH / Other |
- Primary Purpose: Treatment
|
|
|
All |
up to 21 Years (Child, Adult) |
NCT00019422 |
CDR0000066169
NCI-98-C-0074H
CCG-09716
ALK-01-041
NCI-T98-0011
COG-C09716 |
|
March 1998 |
|
April 2003 |
January 27, 2003 |
August 16, 2013 |
|
- University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States - University of South Alabama Medical Center
Mobile, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - (and 233 more...)
|
| 48 |
NCT03126266 |
Recruiting |
Re-Irradiation of Progressive or Recurrent DIPG |
- Recurrent or Progressive Diffuse Intrinsic Pontine Glioma
|
- Radiation: re-irradiation
|
Interventional |
Not Applicable |
- University of Calgary
- Meagan's Walk
- Janeway Child Health Centre
- (and 12 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- second progression-free survival
- overall survival
|
25 |
All |
up to 17 Years (Child) |
NCT03126266 |
HREBA.CC16-0143 |
|
April 15, 2017 |
October 2021 |
October 2021 |
April 24, 2017 |
October 26, 2017 |
|
- Alberta Children's Hospital
Calgary, Alberta, Canada
|
| 49 |
NCT02000986 |
Withdrawn |
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors |
- Childhood Brain Tumor
- Childhood Hodgkin Lymphoma
- Childhood Non-Hodgkin Lymphoma
- Malignant Childhood Neoplasm
|
- Behavioral: Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
|
Interventional |
Not Applicable |
- Virginia Commonwealth University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Feasibility determined by average attendance and retention
- Feasibility determined by average attendance and retention from the blood pressure at enrollment
- Acceptability level at time of enrollment
|
0 |
All |
11 Years to 17 Years (Child) |
NCT02000986 |
MCC-14062
HM14062 |
|
August 2012 |
March 2015 |
July 2015 |
December 4, 2013 |
November 20, 2015 |
|
|
| 50 |
NCT01861990 |
Withdrawn |
Valproic Acid in Childhood Progressive Brain Tumors |
- Pediatric Brain Tumor
- Glioma
- Anaplastic Astrocytoma
- (and 2 more...)
|
|
Interventional |
Phase 1 |
- Medical University of South Carolina
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Completion of protocol
- Time to progression
|
0 |
All |
1 Year and older (Child, Adult, Senior) |
NCT01861990 |
VA2013
IRG-97-219-14 |
|
May 2013 |
December 2013 |
December 2013 |
May 24, 2013 |
May 22, 2015 |
|
- Medical University of South Carolina
Charleston, South Carolina, United States
|
Create an RSS feed from your search for:
Download the search results for: